Angle PLC Announces Change of Adviser
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.
The company, which focuses on innovative solutions for research, drug development, and clinical oncology, made this change in its advisory relationships to support its ongoing business operations. The appointment demonstrates ANGLE's commitment to maintaining strong market relationships and corporate governance standards.
Details
News Market Reaction – ANPCY
On Sep 9, the day this news came out, ANPCY closed 23.52% below the previous close.
Data tracked by StockTitan Argus for the Sep 9 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser and Sole Broker with immediate effect.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) | +44 (0) 20 7220 0500 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.